Rapamycin Prolongs Survival and Arrests Pathophysiologic Changes in Murine Systemic Lupus Erythematosus

Arthritis & Rheumatism

Volumn 37, Issue 2, 1994, Pages 289-297

  Warner, Linda M ^a,b   Adams, L M ^a,b   Sehgal, S N ^a,b  

^a PFIZER INC   (United States)

^b Sphinx Pharmaceuticals Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CONCANAVALIN A; CYCLOSPORIN A; DNA ANTIBODY; INTERLEUKIN 2; RAPAMYCIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GLOMERULONEPHRITIS; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; SPLEEN CELL; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADMINISTRATION, ORAL; ALBUMINURIA; ANIMALS; ANTIBODIES, ANTINUCLEAR; CYCLOSPORINE; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, MUTANT STRAINS; POLYENES; SIROLIMUS; SURVIVAL ANALYSIS;

EID: 0028107540     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.1780370219     Document Type: Article

References (32)

1. Etio‐pathogenesis of the rheumatoid arthritis–like disease in MRL/1 mice. I. The histomorphologic basis of joint destruction
2. Long term therapeutic study with immunomodulators or interleukin‐2 on the pulmonary lesions in MRL/1 mice
3. Deletion of potentially self‐reactive T cell receptor specificities in L3T4–, Lyt‐2– T cells of Ipr mice
4. Delineation of two defects responsible for T cell hyporesponsiveness to concanavalin A in MRL congenic mice
5. Development of autoimmunity in MRL/lpr mice and the effects of drugs on this murine disease
6. Inhibition of in vitro anti‐dsDNA B cell responses by cyclosporin
7. CsA therapy in MRL‐lpr/lpr mice: amelioration of immunopathology despite autoantibody production
8. Effects of cyclosporin A on autoimmune disease in MRL/1 and BXSB mice
9. Effect of FK506, a novel immunosuppressive drug on murine systemic lupus erythematosus
10. Rapamycin (AY‐22, 989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle
11. Rapamycin (AY‐22, 989), a new antifungal antibiotic: 2. Fermentation, isolation and characterization
12. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK‐506 and rapamycin
13. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with CsA and FK506, and effect on host‐versus‐graft and graft‐versus‐host reactions
14. Preclinical evaluation of a new potent immunosuppressive agent, rapamycin
15. Inhibition of the immune response by rapamycin, a new antifungal antibiotic
16. Rapamycin prevents the onset of insulin‐dependent diabetes mellitus (IDDM) in NOD mice
17. In vitro stimulation of murine spleen cells using a microculture system and a multiple automated sample harvester
18. Lymphocyte activation. V. Question of the proliferative responses to mitogens using defined T and B cell populations
19. Long term culture of tumor‐specific cytotoxic T cells
20. Deficient phytohemagglutinin‐induced interleukin‐2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate
21. Systemic lupus erythematosus
22. Measurement of increases in anti–double‐stranded DNA antibody levels as a predictor of disease exacerbations in systemic lupus erythematosus: a long‐term, prospective study
23. Immunosuppressive activity of rapamycin versus cyclosporin A (abstract)
24. Immunoregulation in MRL/Mp‐Ipr/lpr mice: evidence for decreased helper‐T‐cell and increased suppressor‐T‐cell function with age
25. Alleviation of autoimmune disease in MRL‐lpr mice by administration of Ye 19.1, a monoclonal specific for the Ipr T cell antigen, LTA
26. Identification of a B‐cell differentiation factor(s) spontaneously produced by proliferating T‐cells in murine lupus strains of the Ipr/lpr genotype
27. Autoreactivity accelerates the development of autoimmunity and lymphoproliferation in MRL/MP‐lpr/lpr Mice
28. Inhibition of T and B lymphocyte proliferation by rapamycin
29. Rapamycin selectively inhibits interleukin‐2 activation of p70 S6 kinase
30. Autoreactive T cells in MRL/MP‐lpr/lpr mice: characterization of the lymphokines produced and analysis of antigen‐presenting cells required
31. Antigen presentation by resting B cells: radiosensitivity of the antigen‐presentation function and two distinct pathways of T cell activation
32. Interleukin‐1 and interferon‐gamma: cytokines that provide reciprocal regulation of macrophage and T cell function